Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1081 to 1082 of 1082 entries
Sorted by: Best Match Show Resources per page
Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Kim J, Kim JY, Lee JH, Sinn DH, Hur MH, Hong JH, Park MK, Cho HJ, Choi NR, Lee YB, Cho EJ, Yu SJ, Kim YJ, Paeng JC, Kim HC, Yi NJ, Lee KW, Suh KS, Hyun D, Kim JM, Yoon JH.
PMID: 34887340
J Nucl Med. 2021 Dec 09; doi: 10.2967/jnumed.121.263147. Epub 2021 Dec 09.

The surgical treatment for large hepatocellular carcinoma (HCC) remains controversial due to a high risk of recurrence after resection. This study aimed to compare long-term outcomes of transarterial radioembolization (TARE) with resection for patients with large HCC.

Cite
Kim J, Kim JY, Lee JH, et al. Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection. J Nucl Med. 2021;doi: 10.2967/jnumed.121.263147.
Kim, J., Kim, J. Y., Lee, J. H., Sinn, D. H., Hur, M. H., Hong, J. H., Park, M. K., Cho, H. J., Choi, N. R., Lee, Y. B., Cho, E. J., Yu, S. J., Kim, Y. J., Paeng, J. C., Kim, H. C., Yi, N. J., Lee, K. W., Suh, K. S., Hyun, D., Kim, J. M., & Yoon, J. H. (2021). Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, . https://doi.org/10.2967/jnumed.121.263147
Kim, Jihye, et al. "Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. (2021). doi: https://doi.org/10.2967/jnumed.121.263147
Kim J, Kim JY, Lee JH, Sinn DH, Hur MH, Hong JH, Park MK, Cho HJ, Choi NR, Lee YB, Cho EJ, Yu SJ, Kim YJ, Paeng JC, Kim HC, Yi NJ, Lee KW, Suh KS, Hyun D, Kim JM, Yoon JH. Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection. J Nucl Med. 2021 Dec 09; doi: 10.2967/jnumed.121.263147. Epub 2021 Dec 09. PMID: 34887340.
Copy Download .nbib Format: NLM
Dioscin ameliorates diabetes cognitive dysfunction via adjusting P2X7R/NLRP3 signal.

International immunopharmacology

Lu Z, Yao Y, Wang J, Peng JY.
PMID: 34785142
Int Immunopharmacol. 2021 Dec;101:108314. doi: 10.1016/j.intimp.2021.108314. Epub 2021 Nov 14.

Dioscin presents extents of pharmacological activities on several diseases, but its effect and mechanism on diabetes cognitive dysfunction (DCD) remains unclear. Herein, we conducted a series of pharmacological evaluation assays of purinergic receptor P2X7 (P2X7R) with dioscin. We uncovered...

Cite
Lu Z, Yao Y, Wang J, et al. Dioscin ameliorates diabetes cognitive dysfunction via adjusting P2X7R/NLRP3 signal. Int Immunopharmacol. 2021;101:108314doi: 10.1016/j.intimp.2021.108314.
Lu, Z., Yao, Y., Wang, J., & Peng, J. Y. (2021). Dioscin ameliorates diabetes cognitive dysfunction via adjusting P2X7R/NLRP3 signal. International immunopharmacology, 101108314. https://doi.org/10.1016/j.intimp.2021.108314
Lu, Zhi, et al. "Dioscin ameliorates diabetes cognitive dysfunction via adjusting P2X7R/NLRP3 signal." International immunopharmacology vol. 101 (2021): 108314. doi: https://doi.org/10.1016/j.intimp.2021.108314
Lu Z, Yao Y, Wang J, Peng JY. Dioscin ameliorates diabetes cognitive dysfunction via adjusting P2X7R/NLRP3 signal. Int Immunopharmacol. 2021 Dec;101:108314. doi: 10.1016/j.intimp.2021.108314. Epub 2021 Nov 14. PMID: 34785142.
Copy Download .nbib Format: NLM
Showing 1081 to 1082 of 1082 entries